跳到主要內容

Goldsmith Mark A 的 Form 4 申報

Revolution Medicines, Inc.(RVMD),2024/6/5 申報

申報編號
0001610717-24-000285
申報時間
2024/6/5
交易日
2024/6/3
申報延遲
2 天
10b5-1 計畫
有勾選

這份申報列了 4 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $30.0 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Goldsmith Mark ACIK 0001246842董事、高階主管(見申報備註)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2024/6/3Common StockM行使選擇權取得+7,500$4.09+$30,675329,822直接
2024/6/3Common StockS賣出處分−900$39.09F4−$35,181328,922直接
2024/6/3Common StockS賣出處分−5,699$39.99F5−$227,903.01323,223直接
2024/6/3Common StockS賣出處分−901$40.93F6−$36,877.93322,322直接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2024/6/3Common StockM行使選擇權處分−7,500$0.00$0316,229直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F4

This transaction was executed in multiple trades in prices ranging from $38.41 to $39.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F5

This transaction was executed in multiple trades in prices ranging from $39.41 to $40.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F6

This transaction was executed in multiple trades in prices ranging from $40.50 to $41.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

備註

President and Chief Executive Officer

看 SEC EDGAR 上的完整原文 (在新分頁開啟)